ID
32578
Descripción
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma
Palabras clave
Versiones (2)
- 7/11/18 7/11/18 -
- 7/12/18 7/12/18 -
Titular de derechos de autor
GSK group of companies
Subido en
7 de noviembre de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837
Patient's Diary Card 1: Screening/Run-In Visit 1
- StudyEvent: ODM
Descripción
Daily Assessments
Descripción
Date
Tipo de datos
text
Descripción
0 = No symptoms during the day or previous night 1 = Symptoms for one short period during the day or previous night 2 = Symptoms for two or more short periods during the day or previous night 3 = Symptoms for most of the day or previous night which did not affect my normal activities 4 = Symptoms for most of the day or previous night which did affect my normal activities 5 = Symptoms so severe that I could not go to work or perform normal activities Circle only one number
Tipo de datos
text
Descripción
if nono, enter zero (0)
Tipo de datos
integer
Similar models
Patient's Diary Card 1: Screening/Run-In Visit 1
- StudyEvent: ODM
Sin comentarios